2025-02-25
Vorinostat
Significant progress has been made in the field of oncology, with the histone deacetylase inhibitor vorinostat showing promising results in treating various cancers in recent clinical trials. Vorinostat was initially approved by the FDA in 2006 for the treatment of cutaneous T-cell lymphoma and has since gained attention for its potential use in other malignancies, including breast cancer, lung cancer, and multiple myeloma.